Esperion Therapeutics, Inc. (ESPR) Shares Sold by UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. cut its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 79.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 39,198 shares of the biopharmaceutical company’s stock after selling 147,954 shares during the quarter. UBS Asset Management Americas Inc. owned 0.17% of Esperion Therapeutics worth $1,814,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. FMR LLC increased its position in shares of Esperion Therapeutics by 70.8% during the 1st quarter. FMR LLC now owns 1,308,588 shares of the biopharmaceutical company’s stock valued at $46,206,000 after purchasing an additional 542,579 shares during the period. Credit Suisse AG grew its holdings in shares of Esperion Therapeutics by 26.4% in the 1st quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock worth $31,030,000 after acquiring an additional 183,440 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Esperion Therapeutics by 20.5% in the 1st quarter. Vanguard Group Inc. now owns 724,150 shares of the biopharmaceutical company’s stock worth $25,569,000 after acquiring an additional 123,318 shares during the last quarter. Meditor Group Ltd acquired a new position in shares of Esperion Therapeutics in the 2nd quarter worth $26,194,000. Finally, State Street Corp grew its holdings in shares of Esperion Therapeutics by 73.3% in the 1st quarter. State Street Corp now owns 413,222 shares of the biopharmaceutical company’s stock worth $14,592,000 after acquiring an additional 174,740 shares during the last quarter. Institutional investors own 83.30% of the company’s stock.

A number of equities analysts recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and issued a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Bank of America Corporation restated a “neutral” rating and issued a $60.00 target price on shares of Esperion Therapeutics in a report on Friday, August 11th. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th. Northland Securities restated a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Finally, Jefferies Group LLC upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and decreased their target price for the stock from $85.00 to $55.00 in a report on Tuesday, August 8th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $58.92.

Shares of Esperion Therapeutics, Inc. (ESPR) opened at 52.98 on Tuesday. The firm’s market cap is $1.20 billion. The stock has a 50 day moving average price of $51.52 and a 200 day moving average price of $43.30. Esperion Therapeutics, Inc. has a 12 month low of $9.40 and a 12 month high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.67) by ($0.25). During the same quarter last year, the company posted ($0.62) EPS. On average, equities research analysts expect that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Esperion Therapeutics, Inc. (ESPR) Shares Sold by UBS Asset Management Americas Inc.” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://transcriptdaily.com/2017/10/17/esperion-therapeutics-inc-espr-shares-sold-by-ubs-asset-management-americas-inc.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply